ATMP2030

SYSTEM TRANSFORMATION TO MAKE SWEDEN WORLD LEADING IN ATMP BY 2030

The project aims to establish a ’Vision Driven Innovation Milieu’ for long-term transformation of the systems required for successful development and implementation of advanced therapy gene and cell therapeutic products, Advanced Therapy Medicinal Products (ATMP). ATMP2030 will be an inclusive platform with a common vision that brings together relevant stakeholders. This project is based on the Vinnova Vision Driven Health program. Important intermediate goals are a national pool of power and increased internationalization, better conditions for the development and accessibility of advanced therapies, as well as increased knowledge of the area to secure future competence needs.

Coordinator: RISE Research Institutes of Sweden AB – RISE Bioscience and Materials

Partners: Akademiska Sjukhuset, Apotekarsocieteten, Astra Zeneca, CombiGene, Mendus, Karolinska Universitetssjukhuset, Läkemedelsakademin, LIF, Läkemedelsverket, MSC Nordics, NextCell Pharma, Region Skåne, Region Västerbotten, Region Örebro , Region Östergötland, SKR, Umeå universitet, VERIGRAFT, Västra Götalandsregionen, XNK Therapeutics

Subgoals

  • National coordination and strengthening of the network, as well as increased international contacts and collaborations
  • Increased capacity for industrial development and manufacture of ATMPs in Sweden
  • Effective processes for availability of cost-effective ATMPs within Swedish healthcare
  • Increase knowledge and secure future competence needs
  • Organization and financing model for sustainable continuation

Working to make ‘Sweden a world leader in development and implementation of advanced therapies by 2030’

Contact: Jim Lund

Related content

Become a partner

Help us to revolutionise healthcare! Build a partnership with our organisation.

Sign up to our newsletter

The ATMP newsletter is a quarterly newsletter updating on Swedish ATMP developments.